BlackRock Group’s GenMark Diagnostics, Inc GNMK Stock Holding History

BlackRock Group’s Portfolio GNMK Stock Details GNMK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$271K	Buy	22,109 +3,379	+18%	+$40.1K	﹤0.01%	2571
2016 Q3	$221K	Buy	18,730 +8,641	+86%	+$83.4K	﹤0.01%	2602
2016 Q2	$88K	Hold	10,089	–	–	﹤0.01%	2821
2016 Q1	$53K	Buy	10,089 +6,039	+149%	+$33.6K	﹤0.01%	2912
2015 Q4	$31K	Hold	4,050	–	–	﹤0.01%	2888
2015 Q3	$32K	Buy	+4,050	New	+$37.5K	﹤0.01%	2915
2015 Q1	–	Sell	-1,389	Closed	-$19K	–	2906
2014 Q4	$19K	Hold	1,389	–	–	﹤0.01%	2830
2014 Q3	$12K	Buy	+1,389	New	+$14.9K	﹤0.01%	2797

Other funds holding GNMK

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

CCM

Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock Group's GNMK Position: Q4 2016 in Review

BlackRock Group increased its GenMark Diagnostics, Inc (GNMK) stake by 18% in Q4 2016, buying an estimated $40.1K and bringing the position to 22,109 shares worth $271K. The position accounts for ﹤0.01% of the portfolio, ranked #2571.

BlackRock Group first reported a position in GNMK in Q3 2014 and has held it in 8 quarters since. 90 funds tracked by Wall St. Rank hold GNMK as of Q4 2016.

BlackRock Group held 22,109 shares of GenMark Diagnostics, Inc worth $271K as of Q4 2016.
BlackRock Group bought 3,379 GenMark Diagnostics, Inc shares in Q4 2016, an estimated $40.1K.
GenMark Diagnostics, Inc made up ﹤0.01% of BlackRock Group's portfolio in Q4 2016, its #2571 holding.
BlackRock Group first reported a position in GenMark Diagnostics, Inc in Q3 2014 and has held it in 8 quarters since.
90 funds tracked by Wall St. Rank held GenMark Diagnostics, Inc as of Q4 2016.

Based on BlackRock Group's 13F filing for Q4 2016, filed 10 Feb 2017.